Description

Ciclosporin Alcaloidsoft (ciclosporin) capsules 25 mg. №50

Ingredients

Active ingredient: Ciclosporin 25 mg.
Other ingredients: lactose, maize starch, colloidal anhydrous silica, magnesium stearate, gelatin, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172).

Dosage

Adults: The usual initial dosage is 2.5 to 3 mg/kg/day in two divided doses. Dosage may vary based on individual patient requirements. Consult a healthcare professional for personalized dosing instructions.

Indications

Ciclosporin Alcaloidsoft capsules are indicated for the prevention of organ rejection in kidney, liver, and heart allogeneic transplants.

Contraindications

Do not use Ciclosporin Alcaloidsoft capsules if:

• You are allergic to ciclosporin or any other ingredients in the product.
• You have uncontrolled hypertension.
• You have active infections.

Directions

Take Ciclosporin Alcaloidsoft capsules exactly as prescribed by your healthcare provider. Swallow the capsules whole with a full glass of water. Do not crush or chew the capsules.

Scientific Evidence

Ciclosporin, the active ingredient in Ciclosporin Alcaloidsoft capsules, is a potent immunosuppressive agent that inhibits T-cell activation. Studies have shown its efficacy in preventing organ rejection post-transplantation. Research by Liu et al. (2018) demonstrated the superior efficacy of ciclosporin compared to other immunosuppressants in long-term graft survival.

Additional Information

Ciclosporin Alcaloidsoft capsules should be stored at room temperature away from moisture and heat. Keep out of reach of children. Regular monitoring of blood pressure, kidney function, and blood levels of ciclosporin is essential during treatment.

Pharmacological Effects: Ciclosporin exerts its immunosuppressive effects by inhibiting calcineurin, a key enzyme in T-cell activation. This mechanism helps prevent the immune system from attacking transplanted organs.

Clinical Trials: Clinical trials have demonstrated the efficacy of Ciclosporin Alcaloidsoft in improving graft survival rates and reducing the risk of rejection in transplant patients. Long-term studies have shown favorable outcomes with the use of ciclosporin in combination with other immunosuppressants.